Find policies, billing codes, payers, states, and providers
Thyroid Disease Testing
Customize your policy alerts
Sign up for Blue Cross Blue Shield - New Mexico Policy RPLAB019 alerts
Get alerted when Policy RPLAB019 changes without checking for updates manually.
Monitor payer policy activity
Defines BCBSNM reimbursement criteria for laboratory testing of thyroid function (TSH, T4, T3, antibodies, thyroglobulin, etc.) including indications, monitoring intervals, reflex testing, and exclusions for covered members and providers submitting claims to Blue Cross Blue Shield - New Mexico.
Reimbursement Information was edited and divided into multiple criteria to create a cascade approach for TSH vs fT4/fT3/TT3, adding distinct follow-up and monitoring sections.
New criteria were added for follow-up testing of abnormal TSH results, monitoring TSH and fT4 when allowed, and monitoring fT4 without TSH for secondary hypothyroidism.
Testing for thyroxine-binding globulin (TBG), TRH, reverse T3, or T3 uptake is explicitly not reimbursable.
A general statement was added that testing for thyroid markers already addressed within the policy is not reimbursable for indications already covered (e.g., routine general exam without abnormal findings).
Several specific coverage indications and intervals were added or clarified (e.g., one-time TSH screening criteria, monitoring intervals for hypothalamic-pituitary disease, TSH testing for individuals with pregnancy losses or thyroid nodules).
Reimbursement and Coverage Criteria for Thyroid Testing
Reimbursable tests, monitoring, reflex testing, and exclusions
Covered when the following grouped conditions and monitoring/reflex algorithms are met:
ALL of the following
- Note: Signs and symptoms of hypothyroidism and hyperthyroidism are listed in the policy to guide appropriate diagnostic testing.
Providers should order TSH as the first-line test in indicated situations and follow policy-specified reflex and monitoring tests. Claims require appropriate documentation and applicable product Plan rules.
Thyroid testing reimbursement criteria (condensed)
Condensed numbered cascade summarizing reimbursement and monitoring rules:
ALL of the following
- 1) First-line testing: TSH is the appropriate initial test in the situations listed in the policy; testing frequency is indicated in the criteria (e.g., up to once every 6 weeks for many diagnostic indications).
- 2) Follow-up for abnormal TSH: When TSH is abnormal, follow-up reflex testing with fT4 and, as appropriate, fT3/TT3 is reimbursable to characterize thyroid dysfunction.
- 3) Monitoring when fT4-first acceptable: New criteria allow monitoring of TSH and fT4 when conditions permit initial monitoring of fT4 without requiring an abnormal TSH; specific monitoring intervals are provided by condition.
- 4) Secondary (central) hypothyroidism: Monitoring of fT4 without additional TSH measurement is allowed; frequency specified (every 6 weeks with dose changes, annually when stable).
- 5) Antibody and pregnancy-related testing: Policy specifies reimbursable antibody testing intervals (e.g., once every 3 years for certain patients) and additional tests for pregnant/postpartum individuals with hyperthyroidism (TT4, Tg-Ab, TRAb, TPOAb).
- 6) Hypothalamic-pituitary disease: Monitor TSH and fT4 biannually if <18 years and annually if ≥18 years.
- 7) One-time TSH screening: One-time screening is reimbursable for asymptomatic high‑risk individuals (e.g., personal/family history of thyroid dysfunction or type 1 diabetes, other listed subgroups) and certain pediatric indications (short stature, failure-to-thrive).
- 8) Nonreimbursable markers: Testing for TBG, TRH, reverse T3, or T3 uptake is explicitly not reimbursable.
- 9) Other nonreimbursable situations: Testing for thyroid markers addressed by this policy is not reimbursable in circumstances not covered by the listed criteria (e.g., routine general exam without abnormal findings).
Procedure Codes and Frequency Rules
| 80438 | TRH STIMULATION PANEL |
| 80439 | TRH STIMULATION PANEL |
| 83519 | RIA NONANTIBODY |
| 83520 | IMMUNOASSAY QUANT NOS NONAB |
| 84432 | ASSAY OF THYROGLOBULIN |
| 84436 | ASSAY OF TOTAL THYROXINE |
| 84439 | ASSAY OF FREE THYROXINE |
| 84442 | ASSAY OF THYROID ACTIVITY |
| 84443 | ASSAY THYROID STIM HORMONE |
| 84445 | ASSAY OF TSI GLOBULIN |
| 83520 | Thyroxine (T4) total or free (code added to policy history) |
Documentation, Authorization, and Ordering Guidance
Documentation and claims submission requirements
Providers must submit accurate documentation of services performed and code claims using valid HIPAA-approved code combinations; claims are subject to code edit protocols and claim review. Upon request, providers should supply additional documentation and verify coding aligns with industry standards and Plan documents.
- Submit claims using valid code combinations from HIPAA-approved code sets (e.g., CPT, HCPCS, ICD-10-CM).
- Claims are subject to code edit protocols and claim review, including provider contract language, medical/reimbursement policies, and coding software logic.
- Be prepared to provide additional documentation upon request to support medical necessity and coding choices.
- Review applicable Plan documents because not all policy requirements apply to every product.
Prior authorization and ordering guidance (summary)
Order TSH as the first-line test in the specified indications and follow the policy's reorganized numbered cascade for follow-up and monitoring: when TSH is abnormal, obtain reflex testing (fT4, TT3/fT3) as indicated; monitor fT4 without additional TSH for secondary (central) hypothyroidism per specified intervals; and adhere to the policy's stated monitoring frequencies for pregnancy, treatment changes, and chronic conditions.
- Use TSH as first-line testing in situations listed in CC1 and follow the cascade introduced in the updated Reimbursement Information (new #1–#4).
- If TSH is abnormal, obtain reflex follow-up testing with free T4 and T3 assays as appropriate (new follow-up criteria).
- For secondary (central) hypothyroidism, monitor with fT4 testing every 6 weeks after dosage changes and annually when stable (new monitoring criterion).
- Follow specified monitoring intervals: e.g., pregnant/postpartum symptomatic individuals every 4 weeks; primary hypothyroidism every 6 weeks with dose changes and annually when stable; hypothalamic‑pituitary disease biannually if <18 y and annually if ≥18 y.
Key Definitions, Reflex Testing, Screening, and Nonreimbursable Markers
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.